

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease

Nikolaou, Nikolaos; Gathercole, Laura L.; Marchand, Lea; Althari, Sara; Dempster, Niall J.; Green, Charlotte J.; Van De Bunt, Martijn; Mcneil, Catriona; Arvaniti, Anastasia; Hughes, Beverly A.; Sgromo, Bruno; Gillies, Richard S.; Marschall, Hanns-ulrich; Penning, Trevor M.; Ryan, John; Arlt, Wiebke; Hodson, Leanne; Tomlinson, Jeremy W.

DOI:

[10.1016/j.metabol.2019.153947](https://doi.org/10.1016/j.metabol.2019.153947)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Nikolaou, N, Gathercole, LL, Marchand, L, Althari, S, Dempster, NJ, Green, CJ, Van De Bunt, M, Mcneil, C, Arvaniti, A, Hughes, BA, Sgromo, B, Gillies, RS, Marschall, H, Penning, TM, Ryan, J, Arlt, W, Hodson, L & Tomlinson, JW 2019, 'AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease', *Metabolism*, vol. 99, 153947, pp. 67-80.
<https://doi.org/10.1016/j.metabol.2019.153947>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Nikolaou, N. et al. (2019) AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease, *Metabolism*, vol. 99, pages 27-80, DOI: 10.1016/j.metabol.2019.153947

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 24. Apr. 2024



AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease

Nikolaos Nikolaou^a, Laura L. Gathercole^{a,b}, Lea Marchand^a, Sara Althari^a, Niall J. Dempster^a, Charlotte J. Green^a, Martijn van de Bunt^a, Catriona McNeil^a, Anastasia Arvaniti^{a,b}, Beverly A. Hughes^d, Bruno Sgromo^e, Richard S. Gillies^e, Hanns-Ulrich Marschall^f, Trevor M. Penning^g, John Ryan^c, Wiebke Arlt^d, Leanne Hodson^a, Jeremy W. Tomlinson^{a,*}

^a Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK

^b Department of Biological and Medical Sciences, Oxford Brookes University, Oxford OX3 0BP, UK

^c Translational Gastroenterology Unit, University of Oxford, Oxford, UK

^d Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

^e Department of Upper GI Surgery, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

^f Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden

^g Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, 1315 BRB II/III 421 Curie Blvd, Philadelphia, PA 19104-6160, United States of America

ARTICLE INFO

Article history:

Received 10 May 2019

Accepted 18 July 2019

Available online xxxx

Keywords:

NAFLD
5 β -Reductase
Diabetes
Bile acids
Triglyceride
FXR

ABSTRACT

Objective: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5 β -reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis.

Methods: Human liver biopsies were obtained from 34 obese patients and AKR1D1 mRNA expression levels were measured using qPCR. Genetic manipulation of AKR1D1 was performed in human HepG2 and Huh7 liver cell lines. Metabolic assessments were made using transcriptome analysis, western blotting, mass spectrometry, clinical biochemistry, and enzyme immunoassays.

Results: In human liver biopsies, AKR1D1 expression decreased with advancing steatosis, fibrosis and inflammation. Expression was decreased in patients with type 2 diabetes. In human liver cell lines, AKR1D1 knockdown decreased primary bile acid biosynthesis and steroid hormone clearance. RNA-sequencing identified disruption of key metabolic pathways, including insulin action and fatty acid metabolism. AKR1D1 knockdown increased hepatocyte triglyceride accumulation, insulin sensitivity, and glycogen synthesis, through increased *de novo* lipogenesis and decreased β -oxidation, fueling hepatocyte inflammation. Pharmacological manipulation of bile acid receptor activation prevented the induction of lipogenic and carbohydrate genes, suggesting that the observed metabolic phenotype is driven through bile acid rather than steroid hormone availability.

Conclusions: Genetic manipulation of AKR1D1 regulates the metabolic phenotype of human hepatoma cell lines, driving steatosis and inflammation. Taken together, the observation that AKR1D1 mRNA is down-regulated with advancing NAFLD suggests that it may have a crucial role in the pathogenesis and progression of the disease.

© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The global burden of metabolic disease, including obesity, type 2 diabetes mellitus (T2DM) and its hepatic manifestation, non-alcoholic fatty liver disease (NAFLD), continues to escalate. NAFLD is common,

with an unselected population prevalence of 30%, rising to over 80% in obese T2DM patients. It is a spectrum of disease ranging from simple steatosis through to inflammation (non-alcoholic steatohepatitis, NASH) and eventual scarring, fibrosis and cirrhosis with a significant risk of development of hepatocellular carcinoma (HCC) alongside increased cardiovascular mortality [1]. NAFLD is rapidly becoming the leading indication for liver transplantation [2]. Despite the magnitude of the clinical problem, defining the precise molecular pathways that drive lipid accumulation and have potential as therapeutic targets have proved complex.

* Corresponding author at: Oxford centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK.

E-mail address: jeremy.tomlinson@ocdem.ox.ac.uk (J.W. Tomlinson).

Steroid hormones, including glucocorticoids and androgens, are potent regulators of metabolic phenotype and have been implicated in driving hepatic lipid accumulation. Glucocorticoid excess, androgen deficiency in men, and androgen excess in women are all associated with NAFLD [3–5]. Steroid hormone availability is regulated at pre-receptor level within the liver by a series of enzymes, and both genetic and pharmacological manipulation of these enzymes has a profound impact upon metabolic phenotype, including the development of hepatic steatosis [6–8]. Steroid 5 β -reductase (AKR1D1) has an important pre-receptor role in the regulation of steroid hormone action, however, its role in regulating metabolic phenotype has not been explored to date [9]. AKR1D1 is highly expressed in human liver where it generates all 5 β -reduced dihydrosteroid metabolites for C19-, C21- and C27-steroids, *i.e.* androgens, glucocorticoids, and bile acids [10]. In addition to its role in steroid hormone clearance, AKR1D1 has a crucial function in bile acid synthesis. Bile acids are now established as potent signalling molecules that regulate metabolic phenotype acting through previously orphan nuclear receptors, including the farnesoid-X-receptor (FXR). In addition, oxysterols, including bile acid intermediary substrates, are able to also activate the liver-X receptors α and β (LXR α , LXR β) [11]. The activation of both FXR and LXRs have been implicated in the pathogenesis of NAFLD. FXR deletion results in hepatic steatosis, insulin resistance and hyperglycaemia, with evidence suggesting decreased expression in NAFLD [12,13], and FXR agonism has already shown early promise as a therapeutic strategy in NAFLD [14]. In contrast, LXR α expression is increased in NAFLD [11] and LXR α activation drives lipid accumulation whilst suppressing the local inflammatory response [15].

AKR1D1 sits at the interface of two fundamentally important pathways, steroid hormone metabolism and bile acid synthesis, both being potent regulators of hepatic metabolic phenotype. The putative role of AKR1D1 in this regard is almost entirely unexplored; a single study found an association between increased systemic 5 β -reductase activity and hepatic steatosis [16], another demonstrated decreased hepatic 5 β -reductase expression in diabetic patients [17], whilst a third study reported elevated levels of 7- α -hydroxy-4-cholesten-3-one, the bile acid precursor substrate for AKR1D1, in patients with NAFLD [18].

We have therefore hypothesised that decreases in AKR1D1 activity and expression will have a detrimental impact upon hepatic metabolic phenotype, either through decreased bile acid availability or impaired steroid hormone clearance. We have tested this hypothesis through genetic manipulation of *AKR1D1* gene expression as well as investigating expression in human liver biopsies with established NAFLD.

2. Material and methods

2.1. Human studies

Obese male ($n = 7$) and female ($n = 27$) individuals undergoing primary bariatric surgery (laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass) were eligible to be recruited into our dedicated bariatric surgery biobank study (Ref: 16/YH/0247) subject to their written informed consent. Detailed clinical data (including weight, height, medical history, medications, family history and alcohol intake) was recorded for all participants prior to surgery. Intraoperatively, a wedge biopsy was taken from the anatomical left lobe of the liver after pneumoperitoneum was established. Half of this tissue was stored in formalin prior to histological analysis by a consultant liver histopathologist according to Kleiner's NAFLD Activity Score (NAS) and fibrosis staging classification [19]; the remainder was washed in 0.9% NaCl then stored in RNAlater stabilization solution at -80°C until RNA extraction.

2.2. Cell culture

HepG2 cells were a gift from Dr. Karl Morten (University of Oxford), HEK293 cells were a gift from Prof. Anna Gloyn (University of Oxford),

Hep3b cells were a gift from Prof Jane McKeating (University of Birmingham) and Huh7 cells were a gift from Dr. Camilla Pramfalk (Karolinska Institutet). All cells were cultured in Dulbecco's Minimum Essential Medium (DMEM) (Zen Bio Inc., Durham, NC, USA), containing 4.5 g/L glucose, and supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% non-essential amino acids.

The C3A human hepatocyte cell line was purchased from LGC Standards (ATCC - CRL-10741, Middlesex, UK), and cultured in Eagle's Minimum Essential Medium (EMEM) (Sigma-Aldrich, Dorset, UK) containing 4.5 g/L glucose, and supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% non-essential amino acids.

2.3. Primary human hepatocytes

Liver was obtained from patients undergoing surgery who had consented (NRES Committee South Central; Berkshire B 11/SC/0443) to the use of excess tissue (resection surplus) for research. Hepatocytes were dissociated from whole liver tissue via a two-stage collagenase digestion as previously described [20]. Cells were diluted to 1 million cells per mL in William's E buffer containing hepatocyte supplements before plating on Type I collagen coated plates. Cells were collected 24 h post seeding for RNA isolation.

2.4. Transfection studies

For over-expression transfection studies, 1.6×10^5 cells/well were plated in 12-well Cell Bind plates (CORNING, Flintshire, UK) for 24 h prior to transfection with the pCMV6-XL4 + AKR1D1 construct (Origene Technologies, Rockville, USA). 1 μg DNA construct and 2 μL X-tremeGENE DNA transfection Reagent (Roche, Hertfordshire, UK) were diluted in 100 μL OPTIMEM serum-free media (Invitrogen, Paisley, UK). The mixture was vortexed and incubated at room temperature for 20 min and, subsequently, 100 μL was added to each well and cells incubated at 37°C for 48 h prior to treatment.

For knockdown transfection studies, 0.8×10^5 cells/well were plated in 24-well Cell Bind plates (CORNING, Flintshire, UK) for 24 h prior to transfection. To prepare siRNA/lipid solutions for each well of a 24-well plate, 20 nmol of AKR1D1 siRNA (Invitrogen, Paisley, UK) was diluted in 25 μL of OPTIMEM serum free media (Invitrogen, Paisley, UK). In a separate tube, 2.5 μL of Lipofectamine RNAiMAX (Invitrogen, Paisley, UK) was diluted in 25 μL of OPTIMEM. The contents of the two tubes were combined by gentle pipetting and incubated at room temperature for 5 min. The resulting 50 μL of transfection solution was added drop-wise. Finally, cells were then incubated at 37°C for 48 h.

2.5. Cell treatments

Cortisol, cortisone, cholic acid (CA), chenodeoxycholic acid (CDCA), GW4064, 22(S)-Hydroxycholesterol and GSK2033 were purchased from Sigma-Aldrich (Dorset, UK). All cell treatments, including bile acid measurements, were performed in serum-free and phenol-red free media, containing 4.5 g/L glucose (Zen Bio Inc., Durham, NC, USA).

2.6. Steroid hormone measurements

Cortisone was extracted from cell media after addition of the internal standard, cortisol-d4. Briefly, transfected cells were incubated with 200 nM of cortisone for 8 h. 1 mL of media was collected, extracted by SPE and the samples were derivatized overnight to form methyloxime-trimethylsilyl ethers (MO-TMS). The final derivative was dissolved in 55 μL cyclohexane, which was transferred to an auto-sampler vial for gas chromatography-mass spectrometry analysis using an Agilent 5973 instrument (www.agilent.com) in a selected ion monitoring mode.

2.7. Lipid extraction and gas chromatography–mass spectrometry

Total intracellular lipid was extracted and intracellular *de novo* lipogenesis (DNL) measured by the uptake of deuterium from $^2\text{H}_2\text{O}$ (Finnigan GasBench-II, ThermoFisher Scientific, UK) into intracellular triglyceride and PL [^2H]-palmitate. [^2H]-palmitate enrichments were determined by gas chromatography–mass spectrometry using a 5890 GC coupled to a 5973 N MSD (Agilent Technologies; CA, USA). Ions with mass-to-charge ratios (m/z) of 270 ($M + 0$) and 271 ($M + 1$) were determined by selected ion monitoring [21].

2.8. RNA extraction and reverse transcription

Total RNA was extracted from cells using the Tri-Reagent system (Sigma-Aldrich, Dorset, UK). Concentration was determined spectrophotometrically at OD260 on a Nanodrop spectrophotometer (Thermo Scientific, Hemel Hempstead, UK). Reverse transcription was performed in a 20 μL volume; 1 μg of total RNA was incubated with 10 \times RT Buffer, 100 mM dNTP Mix, 10 \times RT Random Primers, 50 U/ μL MultiScribe Reverse Transcriptase and 20 U/ μL RNase Inhibitor (Thermo Scientific, Hemel Hempstead, UK). The reaction was carried out at 25 $^\circ\text{C}$ for 10 min, 37 $^\circ\text{C}$ for 120 min and then terminated by heating to 85 $^\circ\text{C}$ for 5 min.

2.9. Quantitative PCR (qPCR)

All quantitative PCR experiments were conducted using an ABI 7900HT sequence detection system (Perkin-Elmer Applied Biosystems, Warrington, UK). Reactions were performed in 6 μL volumes on 384-well plates in reaction buffer containing 3 μL of 2 \times Kapa Probe Fast qPCR Master Mix (Sigma-Aldrich, Dorset, UK). Life Technologies supplied all primers as predesigned TaqMan Gene Expression Assays labelled with FAM. The reaction conditions were as follows: 95 $^\circ\text{C}$ for 3 min, then 40 cycles of 95 $^\circ\text{C}$ for 3 s and 60 $^\circ\text{C}$ for 20 s. The C_t (dC_t) of each sample using the following calculation (where E is reaction efficiency – determined from a standard curve): $\Delta C_t = E^{[\min C_t - \text{sample } C_t]}$ using the 1/40 dilution from a standard curve generated from a pool of all cDNAs as the calibrator for all samples. The relative expression ratio was calculated using the following: $\text{Ratio} = \Delta C_{t[\text{target}]} / \Delta C_{t[\text{ref}]}$ and expression values were normalised to 18S rRNA, unless stated otherwise [22].

2.10. RNA sequencing

Total RNA was extracted using the Tri-Reagent system (Sigma-Aldrich, Dorset, UK) and enriched for polyA-tailed mRNA using oligo (dT) beads. The Illumina TruSeq Stranded mRNA HT Sample Prep Kit was used to prepare cDNA libraries for sequencing. In-house 8 bp indexes [23] were used to multiplex samples (10-plex), which were then sequenced over 1 lane of an Illumina HiSeq4000 machine using HiSeq 3000/4000 PE Cluster Kit and SBS Kit. Paired-end sequencing (75 bp) was performed at a depth of ~25 million read pairs per sample. Reads were mapped with STAR 2.5.1b [24] on default settings with GENCODE version 19 [25] as transcriptome and GRCh37 as genome reference. Gene level reads counts for all protein-coding and long intergenic non-coding RNA (lincRNA) transcripts present in GENCODE version 19 were quantified in a strand-specific manner with featureCounts [26] from the Subread package v1.5.0-p2. For plotting purposes, we also normalised the gene counts to transcripts per million (TPM). Differential expression analysis was performed using limma [27] in R 3.2.2 on voom-normalised gene counts for all autosomal protein-coding and lincRNA genes that were expressed at >1 count per million (CPM) in all knockdown and/or all control samples. A paired model was fitted to the data, and significance was determined by empirical Bayes moderated t -statistics implemented in limma. Differentially

regulated genes were defined by a false discovery rate (Benjamini-Hochberg method) adjusted p -value <1%.

2.11. Protein extraction and Immunoblotting

Total protein was extracted from cells using RIPA buffer (Sigma-Aldrich, Dorset, UK), protease inhibitor cocktail (1/100) and phosphatase inhibitor cocktail (1/100) (ThermoFisher Scientific, Loughborough, UK). Protein concentrations were measured using a commercially available assay according to the manufacturer's protocol (Bio-Rad, Hemel Hempstead, UK). Primary β -tubulin (#15115, monoclonal), total AKT (#4685, monoclonal), pAKT (#4060, monoclonal), AKT1 (#75692, monoclonal), mTOR (#2983, monoclonal), pGSK3 β (#5558, monoclonal), GSK3 β (#12456, monoclonal), ACC (#3662, polyclonal), pACC (#11818, monoclonal), I κ B α (#4812, monoclonal) from Cell Signalling (Danvers, USA), AKR1D1 (dilution 1/250) (HPA057002, polyclonal, Atlas Antibodies AB, Bromma, Sweden), and secondary antibodies (P044801–2, P044701–2, polyclonal) from Dako (Agilent Technologies, Santa Clara, USA) were used at a dilution of 1/1000 and 1/2000 respectively, unless stated otherwise. To ascertain equal gel loading, proteins were normalised to β -tubulin. Bands were visualised with ECL and ChemiDocXS imager (Biorad, Hemel Hempstead, UK). Western blots were quantified by densitometry analysis using Image J (NIH, Bethesda, MD, <http://rsb.info.nih.gov/ij/>).

2.12. Bile acid measurements

Total bile acid content was measured using a colorimetric assay according to the manufacturer's protocol (Cell Biolabs Inc., San Diego, USA). Total CA and CDCA levels were measured using a competitive ELISA according to the manufacturer's protocol (Cell Biolabs Inc., San Diego, USA).

2.13. Biochemical measurements

Glucose, triglyceride and 3-hydroxybutyrate were analyzed using Instrumentation Laboratory kits on an ILab 650 Clinical Chemistry analyzer as described previously [28]. Complete medium-containing FBS or lysis buffer were used as negative background controls. Intracellular glycogen content was measured using a fluorimetric assay according to the manufacturer's protocol (BioVision Inc., California, USA).

2.14. Statistics

Data are presented as mean \pm standard error. Normal distribution was confirmed using Shapiro-Wilk test. Statistical analysis on qPCR data from human subjects was performed using two-tailed, unpaired t -tests and Fisher's exact t -test. For cell culture experiments, two-tailed, paired t -tests were used to compare single treatments to control. For comparisons between control and different treatments, statistical analysis was performed using one-way analysis of variance (ANOVA) with Dunnett corrections. To compare mean differences between groups that had been split on multiple treatments, doses or times, two-way analysis of variance (ANOVA) with Sidak corrections was used. Statistical analysis on qPCR data was performed on mean relative expression ratio values. Data analysis was performed using Graphpad Prism software (Graphpad Software Inc., La Jolla, USA) and considered statistically significant at $p < 0.05$.

3. Results

3.1. AKR1D1 mRNA expression decreases across the spectrum of NAFLD in humans

AKR1D1 mRNA levels were examined in liver biopsies from obese male and female patients ($n = 34$). A summary of patient characteristics

is provided in Table 1. *AKR1D1* expression was significantly lower in advanced fibrosis (F3–4), when compared to mild to moderate fibrosis (F0–2) (Fig. 1a and b). When biopsies were categorized on the basis of NAFLD activity score (NAS), reflecting the presence of non-alcoholic steatohepatitis (NASH), as well as on the basis of steatosis percentage, *AKR1D1* mRNA levels were lower in those with higher NAS and > 5.5% steatosis (the diagnostic threshold for hepatic steatosis [29,30]) (Fig. 1c–d). In addition, when patients were categorized based on the presence of T2DM, *AKR1D1* mRNA levels were significantly lower in patients with T2DM (Fig. 1e). Endorsing our findings, additional data from publicly available databases were extracted, demonstrating a consistent decrease in *AKR1D1* expression in patients with advanced NAFLD, compared to mild NAFLD (Supplementary Fig. 1) (GEO accession GSE49541; [31,32]).

To define whether the observed differences in *AKR1D1* expression are sex-specific, mRNA analysis was repeated in female subjects only. Consistent with the previous data, in obese female patients, *AKR1D1* expression was significantly lower in advanced fibrosis (F0–1: 0.85 ± 0.06 vs. F3–4: 0.59 ± 0.09 , $p = 0.05$) and in patients with T2DM (Normal: 0.90 ± 0.07 vs. T2DM: 0.60 ± 0.06 , $p < 0.01$).

3.2. *AKR1D1* silencing decreases steroid hormone clearance and bile acid synthesis in human hepatoma cells

In order to investigate the role of *AKR1D1* within the human liver *in vitro*, the expression pattern of *AKR1D1* expression was explored in four different human hepatoma cell lines, using qPCR (Supplementary Fig. 2a). Expression levels in HepG2 and Huh7 were similar to those seen in primary human hepatocytes and these were therefore selected as suitable models for genetic manipulation studies.

siRNA techniques were utilised in both cell lines to decrease *AKR1D1* mRNA levels and effective knockdown was confirmed by qPCR and western blotting (Fig. 2a–c). To confirm the functional impact of *AKR1D1* knockdown on glucocorticoid clearance, HepG2 cells were treated with cortisone (200 nM, 8 h) and cell culture media cortisone and 5 β -tetrahydrocortisone (5 β -reduced metabolite of cortisone, 5 β -THE) levels were measured using GC–MS, and compared against scrambled controls. Consistent with the mRNA and protein data, *AKR1D1* knockdown decreased cortisone clearance and 5 β -THE generation (Supplementary Fig. 2b and c).

Following over-expression of *AKR1D1* in HepG2 and HEK293 cells, cortisone clearance and 5 β -THE generation were increased, providing additional evidence for the potent ability of *AKR1D1* to regulate steroid hormone availability within human hepatoma cells (Supplementary Figs. 2d–g and 3a–d).

Table 1

Clinical and biochemical characteristics of obese patients with mild to moderate fibrosis (F0–2) compared to patients with advanced fibrosis (F3–4) on liver biopsy.

Characteristics	F score		p-Value
	0–2	3–4	
Gender (m/f)	f = 21, m = 1	f = 6, m = 6	
Age (years)	45 \pm 3	49 \pm 3	0.32
BMI (kg/m ²)	48.8 \pm 1.7	48.0 \pm 2.3	0.788
T2DM (%)	18 (4/22)	92 (11/12)***	<0.001
AST (IU/L)	22 \pm 1	32 \pm 5*	0.016
ALT (IU/L)	29 \pm 2	37 \pm 7	0.167
Platelets (x10 ⁹ /L)	269 \pm 11	239 \pm 23	0.198
AST/ALT ratio	0.85 \pm 0.05	0.92 \pm 0.11	0.569
FIB-4 score	0.76 \pm 0.08	1.55 \pm 0.36**	0.007
Ferritin (ug/L)	102 \pm 13	120 \pm 20	0.448
HbA1c (%)	5.5 \pm 0.1	6.4 \pm 0.4**	0.004
Total Chol (mmol/L)	4.6 \pm 0.3	4.0 \pm 0.3	0.16
HDL (mmol/L)	1.0 \pm 0.05	0.8 \pm 0.03**	0.008
LDL (mmol/L)	2.8 \pm 0.2	2.3 \pm 0.3	0.178
Chol/HDL ratio	4.6 \pm 0.2	4.8 \pm 0.3	0.597

As *AKR1D1* plays a crucial role in bile acid synthesis, we examined cell culture media bile acid levels following *AKR1D1* knockdown in both HepG2 and Huh7 cells, revealing decreased total bile acid secretion in the cell culture media (Fig. 2d). Specifically, cell media CA and CDCA levels were reduced (Fig. 2e). In both cell lines, compensatory increases in the mRNA expression of genes involved in primary bile acid synthesis and transport, including *CYP7A1*, *HSD3B7*, *CYP8B1* and *SLC51A*, were observed, in addition to decreases in the expression of the FXR regulated genes *NR0B2* (*SHP*) and *LRH-1*, indicating decreased FXR activation (Fig. 2f and g). Interestingly, a significant increase in the mRNA expression of 5 α -reductase type 1 (*SRD5A1*) was also observed (Fig. 2f and g), suggesting a compensatory mechanism for either steroid clearance or bile acid production.

3.3. *AKR1D1* silencing defines discrete dysregulated metabolic pathways

To gain a broader insight into the role of *AKR1D1* in human hepatoma cells, transcriptome analysis using RNA-sequencing was undertaken in HepG2 cells with *AKR1D1* knockdown. A total of 465 transcripts were differentially expressed as a function of *AKR1D1* knockdown ($p = 4.06 \times 10^{-3}$; logFC = -4.29) compared to scrambled control-transfected HepG2 cells. The top 10% of differentially regulated genes are presented in the heatmap in Fig. 3b. To facilitate wider exploration of molecular processes affected by *AKR1D1* knockdown, a differential expression gene set obtained with a more relaxed significance threshold (FDR 5%) was used to search for enrichment of biological pathways annotated in the Kyoto Encyclopaedia of Genes and Genomes (KEGG). This analysis identified discrete dysregulated metabolic pathways impacting upon a variety of cellular phenotypes, notably, including key pathways impacting insulin action and fatty acid storage and utilization (Fig. 3c).

3.4. *AKR1D1* knockdown enhances insulin sensitivity in human hepatoma cells

Informed by our RNA sequencing data, we undertook a series of experiments to define the precise impact of *AKR1D1* silencing on hepatic insulin sensitivity *in vitro*. In both HepG2 and Huh7 cells, *AKR1D1* knockdown increased the mRNA expression of genes involved in insulin signalling, including *AKT1* and *mTOR*, whilst it decreased insulin receptor expression (*INSR*) (Fig. 4a and b). Consistent with these findings, *AKR1D1* knockdown increased the protein expression of *AKT1* and *mTOR* in both human hepatoma cell lines, indicative of alterations in the activation of the insulin signalling cascade (Fig. 4c and d). Endorsing the changes in protein expression, insulin-stimulated phosphorylation of PKB/akt at serine 473 was increased in both HepG2 and Huh7 cells following *AKR1D1* knockdown, compared to scrambled controls, in a dose-dependent manner (5 nM and 50 nM, 15 min) (Fig. 4e and f).

3.5. *AKR1D1* knockdown drives hepatocyte triglyceride accumulation through enhanced lipogenesis and decreased oxidation

Metabolic assessments were made in HepG2 cells following *AKR1D1* knockdown. mRNA expression of the glucose transporters *GLUT1* and *GLUT9* increased, whilst glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) and glycogen phosphorylase expression (*PYGL*) decreased (Fig. 5a). Consistent with these findings, cell media glucose concentrations were significantly lower (scrambled control: 15.34 ± 1.51 vs. *AKR1D1* knockdown: 12.11 ± 0.90 nmol/mg, $p < 0.05$) and intracellular glycogen storage increased (Fig. 5b). However, no differences in the protein levels of either total or phosphorylated GSK3 β were observed, suggesting that the differences in glycogen accumulation are likely to be due to decreased glycogenolysis rather than increased glycogen synthesis (Fig. 5c). In addition, we observed significant increases in lipogenic gene expression [fatty acid synthase (*FASN*), acetyl co-A carboxylase (*ACC1*), stearoyl-CoA desaturase 1 (*SCD1*) and sterol




Fig. 1. AKR1D1 expression in obese patients. In male ($n = 7$) and female ($n = 27$) obese patients, AKR1D1 mRNA expression decreased with more advanced fibrosis (a–b), steatosis percentage (c) and higher NAFLD Activity Score (NAS) (d). In addition, mRNA expression of AKR1D1 was reduced in patients with T2DM (e). qPCR data were normalised to 18S rRNA, TBP and ACTB. Data are presented as mean \pm se, performed in triplicate, * $p < 0.05$, ** $p < 0.01$.

regulatory element-binding protein 1c (*SREBF1*) and reductions in the expression of enzymes regulating lipid export [ATP-binding cassette subfamily A1 (*ABCA1*)] and oxidation [peroxisome proliferator-activated receptor α (*PPAR* α)] (Fig. 5a). The pattern of changes in gene expression mirrored that observed in the RNA-sequencing analysis (Supplementary Fig. 4).

Consistent with the mRNA expression data, there were increased phosphorylated and total protein levels of ACC in AKR1D1 knockdown HepG2 cells (Fig. 5d). Total cellular triglyceride (TAG) accumulation also increased (scrambled control: 56.9 ± 8.8 vs. AKR1D1 knockdown: 74.1 ± 9.0 nmol/mg, $p < 0.001$), whilst fatty acid oxidation decreased, as measured by reduced 3-hydroxybutyrate concentrations in the cell culture media (Fig. 5e and f). TAG accumulation in hepatocytes can occur via a number of different pathways. *De novo* lipogenesis (DNL) is the synthesis of fatty acids, namely palmitate (16:0), from non-lipid precursors and this was measured by incorporation of deuterated water into cellular TAG and phospholipids. AKR1D1 knockdown increased DNL both in total cellular TAG and in the phospholipid fraction (Fig. 5g). Complementary metabolic assessments were performed in Huh7 cells; the results revealed similar changes with increased lipogenic gene expression, increased ACC protein levels and increased TAG accumulation, following AKR1D1 knockdown (Supplementary Fig. 5).

Parallel metabolic assessments were made in HepG2 cells over-expressing AKR1D1. However, no differences in the expression of genes involved in carbohydrate and lipid metabolism or intracellular TAG accumulation were observed (Supplementary Fig. 6).

3.6. Metabolic effects of AKR1D1 knockdown are dependent upon reduced FXR and increased LXR activation

AKR1D1 knockdown significantly increased the expression of *CYP7A1*, *FASN*, *ACC1*, *SREBF1*, *SCD1*, *AKT1*, *GLUT1* and *GLUT9* in human hepatoma cells. Cortisol treatment (500 nM, 24 h) of HepG2 cells failed to regulate the mRNA expression of these genes, suggesting that the phenotype we observed in our AKR1D1 knockdown experiments was

unlikely to be due to changes in glucocorticoid availability (Supplementary Fig. 7). Additional treatments with CA (50 μ M, 24 h) and CDCA (50 μ M, 24 h) were performed. Whilst CA had no effect on gene expression, CDCA treatment significantly prevented the induction of *CYP7A1*, *FASN*, *SCD1*, *SREBF1*, *AKT1* and *GLUT1* mRNA expression caused by AKR1D1 knockdown (Fig. 6a and b).

We therefore tested the hypothesis that the observed phenotype could arise from decreased FXR activation (due to decreased bile acid synthesis and availability) or increased LXR activation secondary to increased accumulation of oxysterols and bile acid precursors. We proposed that FXR agonism and/or LXR antagonism would have the potential to rescue the phenotype in our cells. The FXR agonist GW4064 (5 μ M, 24 h) and the LXR α antagonist 22(S)-Hydroxycholesterol (22-S HC) (10 μ M, 24 h) decreased *CYP7A1*, *GLUT1*, *FASN* and *SCD1* expression, whilst the LXR α antagonist selectively decreased *SREBF1* expression (Supplementary Fig. 7). Treatment with GW4064 normalised the expression of all target genes to levels seen in scrambled controls (Fig. 6c–j, Supplementary Fig. 8). In addition, co-treatment with 22-S HC partially restored the expression levels of *FASN*, *ACC1*, *SREBF1* and *GLUT9*. Additional experiments using the LXR β antagonist GSK2033 (100 nM, 24 h) resulted in partial rescue of the expression levels of *FASN*, *ACC1* and *SREBF1*, but had no impact on the induction of expression of the other genes caused by AKR1D1 knockdown (Fig. 6c–j, Supplementary Fig. 8). Taken together, these data provide strong evidence that the observed metabolic effects following genetic manipulation of AKR1D1 are mediated by impaired FXR activation and, to a lesser extent, increased LXR activation.

3.7. AKR1D1 knockdown fuels cellular inflammation

Inflammation is a key pathogenic process in the natural history and progression of NAFLD. In HepG2 cells, AKR1D1 knockdown increased the mRNA expression of the pro-inflammatory cytokine IL-8, as well as increased IL-8 secretion into the cell culture media. In addition, AKR1D1 knockdown increased the mRNA expression of inducible nitric oxide synthase (*iNOS*), which is induced in response to an inflammatory




Fig. 2. Genetic manipulation of AKR1D1 in human hepatoma cell lines and bile acid signalling and synthesis in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars), decreased mRNA and protein expression in both HepG2 and Huh7 cells, as measured by qPCR and western blotting (a–c). In both HepG2 and Huh7 cells, AKR1D1 knockdown (white bars) decreased total bile acid concentrations (d). In addition, AKR1D1 knockdown decreased cholic acid (CA) and chenodeoxycholic acid (CDCA) concentrations in Huh7 cells (e). Consistent with these, AKR1D1 knockdown increased the mRNA expression of genes involved in classic bile acid synthesis pathway (CYP7A1, HSD3B7, CYP8B1), bile acid transport (SLC51A), and FXR activation (NR0B2, LRH-1) (f–g). Representative Western blot images are shown, however formal quantification was performed in $n = 7$ –9 replicates. qPCR data were normalised to 18S rRNA. Data are presented as mean \pm se of $n = 5$ –8 experiments, performed in triplicate, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, compared to scrambled controls (black bars).




Fig. 3. RNA sequencing analysis in HepG2 cells, following AKR1D1 knockdown. Transcriptomic profiling of AKR1D1 knockdown in HepG2 cells. Volcano plot illustrating fold-change in expression (\log_2FC) against statistical significance ($-\log_{10}$ adjusted P -values) for all genes. Red dots represent differentially expressed genes as a function of *AKR1D1* knockdown (FDR corrected P -values <0.01) (a). Heat map of the expression changes (normalised counts per million) of the top 10% differentially expressed genes (FDR 1%) in *AKR1D1* knockdown HepG2 cells (red and black bars represent up- and down-regulation, respectively) (b). Top KEGG pathways illustrated as a function of the number of differentially expressed genes contributing to each annotated pathway and coloured with a gradient defined by the statistical significance of pathway enrichment (c). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 4. Insulin signalling in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) altered the mRNA expression of insulin signalling genes, including AKT1, insulin receptor and mTOR, in both HepG2 (a) and Huh7 (b) cells, as measured by qPCR. AKR1D1 knockdown (white bars) increased the protein expression of both AKT1 and mTOR in both cell lines (c and d). Consistent with these data, AKR1D1 knockdown, enhanced insulin sensitivity with increased insulin-stimulated phosphorylation of AKT and mTOR (15 min treatment), in both HepG2 (e) and Huh7 (f) cells. qPCR data were normalised to 18S rRNA and protein data were normalised to β-tubulin. Representative Western blot images are shown from 3 biological replicates, however formal quantification was performed in n = 7–9 replicates. Gene expression data are presented as mean ± se of n = 7 experiments, performed in triplicate, *p < 0.05, **p < 0.01, ***p < 0.001, compared to scrambled controls (black bars).




Fig. 5. Lipid and carbohydrate metabolism in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) increased *GLUT1* and *GLUT9* and decreased *GAPDH* and glycogen phosphorylase (*PYGL*) mRNA expression in HepG2 cells, as measured by qPCR (a). Furthermore, intracellular glycogen storage increased (b), whilst, no differences were observed in total or phosphorylated GSK3β levels, following 15 min insulin stimulation (5 nM, 50 nM) (c). In addition, AKR1D1 knockdown enhanced lipogenic gene expression (*FAS*, *ACC1*, *SCD1*, *SREBF1*) (a), reduced the expression of *ABCA1* and *PPARα* (a), and increased total and phosphorylated ACC protein levels (d). Consistent with the lipogenic and *PPARα* gene expression, AKR1D1 knockdown increased TAG accumulation in HepG2 cells (e) and reduced fatty acid oxidation, as measured by cell media 3-hydroxybutyrate [3OHB] concentrations (f). Moreover, AKR1D1 knockdown increased *de novo* palmitate synthesis in both TAG and phospholipid fraction, as measured by incorporation of ²H from ²H₂O into TAG and phospholipid palmitate, respectively (g). Representative Western blot images are shown from 3 biological replicates, however formal quantification was performed in n = 7–9 replicates. qPCR data were normalised to 18S rRNA and protein data were normalised to β-tubulin. Data are presented as mean ± se of n = 7–8 experiments, performed in triplicate, *p < 0.05, **p < 0.01, ***p < 0.001, compared to scrambled controls (black bars).




Fig. 6. Incremental gene expression following *AKR1D1* knockdown followed by subsequent treatment with CA, CDCA, FXR agonist or LXR antagonist treatment to attempt to rescue the cellular phenotype. CA replacement (50 μ M, 24 h) in the cell culture media failed to prevent upregulation of carbohydrate, lipid or insuling signalling gene expression in *AKR1D1* knocked down HepG2 cells (a). In contrast, CDCA replacement (50 μ M, 24 h) significantly impaired upregulation of the expression of *CYP7A1*, *FASN*, *SCD1*, *SREBF1*, *AKT1* and *GLUT1*, in *AKR1D1* knocked down HepG2 cells (b). Pharmacological manipulation of the bile acid receptor FXR, using the FXR agonist GW4064 (5 μ M, 24 h), also normalised the expression of *CYP7A1*, *FASN*, *ACC1*, *SREBF1*, *SCD1*, *AKT1*, *GLUT1* and *GLUT9* to levels seen in scrambled controls (figure c–h). In addition, treatment with the LXR antagonist 22-S Hydroxycholesterol (22-S HC - 10 μ M, 24 h) and the LXR β antagonist GSK2033 (100 nM, 24 h) partially restored the expression levels of *FASN*, *ACC1* and *SREBF1*, but had no impact on the induction of expression of the other genes caused by *AKR1D1* knockdown (c–h). qPCR data were normalised to 18S rRNA. Data are presented as mean \pm se of incremental gene expression of $n = 3$ –6 experiments, performed in triplicate, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and compared to vehicle treated controls. (KD = *AKR1D1* knockdown).




Fig. 7. Inflammatory response in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) increased the mRNA expression of pro-inflammatory cytokines IL-1 β , IL-6 and IL-8 as did the expression of iNOS in Huh7 and HepG2 cells, as measured by qPCR (a). AKR1D1 knockdown increased the cell media concentrations of IL-8 in HepG2 cells (b), as well as of IL-6 and IL-8 cell media levels in Huh7 cells (c and d). In addition, AKR1D1 knockdown decreased the protein expression levels of I κ B α , the endogenous inhibitor of NF- κ B, which co-ordinates the cellular inflammatory response (e). Pharmacological manipulation of the bile acid receptor FXR, using the FXR agonist GW4064 (5 μ M, 24 h), normalised the expression of IL-1 β in Huh7 cells, only, whilst it had no effect on the expression of IL-6, IL-8 or iNOS in either Huh7 or HepG2 cells (f). qPCR data were normalised to 18S rRNA, protein levels were normalised to β -tubulin and cell media levels were corrected to total protein. Representative Western blot images are shown from 3 biological replicates, however formal quantification was performed in n = 7–9 replicates. Data are presented as mean \pm se of n = 5–8 experiments, performed in triplicate, *p < 0.05, **p < 0.01, ***p < 0.001, compared to scrambled controls (black bars).

insult and has been implicated in the pathogenesis of NAFLD [33] (Fig. 7a and b). Consistent with these findings, *AKR1D1* knockdown increased the mRNA expression of *iNOS* and the expression of the pro-inflammatory cytokines IL-1 β and IL-6 in Huh7 cells (Fig. 7a), alongside increases of both IL-6 and IL-8 secretion in the cell culture media (Fig. 7c and d). Furthermore, protein levels of I κ B α (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor- α), the endogenous inhibitor of NF- κ B that co-ordinates the cellular inflammatory response, were reduced by *AKR1D1* knockdown in Huh7 cells (Fig. 7e).

In order to identify the mechanisms that were responsible for the regulation of the inflammatory response caused by *AKR1D1* knockdown, both HepG2 and Huh7 cells were treated with GW4064 (5 μ M, 24 h) or vehicle, and pro-inflammatory cytokine mRNA expression were explored. In Huh7 cells, GW4064 restored the expression levels of IL-1 β only, but had no impact on the induction of expression of IL-6, IL-8 or *iNOS* caused by *AKR1D1* knockdown. Similarly, GW4064 failed to restore cytokine mRNA expression in HepG2 cells, suggesting, in total, that the inflammatory response caused by *AKR1D1* knockdown is not entirely FXR mediated (Fig. 7f).

4. Discussion

We have provided the first evidence to suggest that *AKR1D1* expression is down-regulated across the spectrum of NAFLD and that this may be crucial in the pathogenesis of the condition. Our *in vitro* experiments have shown that limiting *AKR1D1* expression and activity regulates fundamental metabolic processes within human hepatoma cells that govern hepatic insulin sensitivity, lipid accumulation and carbohydrate metabolism. This leads to a net increase in hepatocyte lipid accumulation and an enhanced inflammatory response.

Consistent with our previous study [9], *AKR1D1* is able to regulate glucocorticoid availability in human hepatoma cells, revealing the presence of an additional pathway for intracellular steroid hormone metabolism within human liver. In healthy human hepatocytes, glucocorticoids can also be metabolised by a variety of other enzymes, including HSD11B1, SRD5A1 and CBR1. However, considering the lack of expression of HSD11B1 and CBR1 in human hepatoma cells, the potential contribution of these enzymes in cortisone metabolism, resulting in differences in the proportion of the 5 β -reduced product, may be small, but cannot be excluded.

Lipid accumulation within hepatocytes is the initial, pre-requisite step in the development of NAFLD. Fatty acid delivery from adipose tissue lipolysis, arising as a consequence of adipose tissue insulin resistance, remains the predominant source of TAG within hepatocytes, however, TAG synthesis *via* DNL increases in importance with NAFLD severity [34,35]. It is plausible that enhanced glucose uptake with *AKR1D1* knockdown may have fuelled the increase in DNL that we observed. Glucose is the most abundant substrate used for DNL. In addition, there is clear evidence that limitation of β -oxidation of fatty acids within hepatocyte mitochondria fuels further TAG accumulation [36]. *AKR1D1* knockdown had a dual effect on DNL and β -oxidation. However, as there is an inverse correlation between hepatic DNL and β -oxidation, where increased malonyl-CoA production leads to decreased oxidation *via* CPT1 inhibition [37], it remains unclear whether the observed decrease in β -oxidation is directly attributable to *AKR1D1* knockdown.

In humans, glucose homeostasis is tightly regulated, and abnormalities in hepatic glucose transport have been linked to NAFLD as well as the development of hepatocellular carcinoma [38,39]. Although GLUT2 is the major glucose transporter in primary human hepatocytes [40], GLUT1 and GLUT9 are the major contributors to glucose influx in hepatoma cells [41]. Gene silencing of *AKR1D1* led to increased glucose flux, with changes in GLUT1 and GLUT9 mRNA expression and reduced cell media glucose levels, suggesting increased glucose transport into the cells. Increased glucose transport and changes in glycogen phosphorylase are likely to underpin the increase in glycogen we observed.

Matching our mechanistic findings, increased intracellular hepatic glycogen content has been described in obese non-diabetic and T2DM patients [42,43].

The mechanisms underpinning our observations are complex, and do not appear to be related to alterations in glucocorticoid availability; cortisol failed to regulate most of the genes that were regulated as a consequence of *AKR1D1* knockdown. In addition, cell treatments with CA had no effect on gene expression either; however, additional CDCA treatments prevented the induction of genes involved in lipid and carbohydrate metabolism and insulating signalling, following *AKR1D1* knockdown. In this regard, the higher potency of CDCA, compared to CA, to activate FXR is well described [44,45], and our data suggested that the observed changes are the result of alterations in CDCA production and FXR activation. FXR activation represses the activity of genes involved in TAG synthesis, including inhibition of the expression of SREBP-1c and *FASN* [46,47]. Consistent with these findings, *AKR1D1* knockdown increased lipogenic gene expression and these changes was abolished following GW4064 treatment, suggesting that the effects of *AKR1D1* knockdown on lipid metabolism are largely, although not exclusively, driven by FXR activation.

The role of FXR in the pathogenesis of metabolic disease and in particular NAFLD is still not fully understood. Genetic deletion of FXR expression has shown a detrimental impact on lipid profiles, insulin sensitivity and hepatic steatosis [48,49]. However, these models are complex, with compensatory increases in bile acid production rates, which also have the potential to impact the metabolic phenotype through activation of alternative bile acid receptors, including TGR5, in a tissue-specific manner.

At a cellular level, FXR activation suppresses SREBP-1c expression in mice [50], an action that is mediated through small heterodimer partner (NR0B2/SHP). In our study, although FXR agonism restored *SREBF1* mRNA expression in the *AKR1D1* knocked down HepG2 cells, no differences were observed in scrambled control-transfected HepG2 cells, following GW4064 treatment (Supplementary Fig. 7f). Therefore, potential differences in the regulation of *SREBF1* by FXR activation between rodents and humans cannot be excluded. In parallel, FXR activation also increases fatty acid oxidation within hepatocytes through induction of PPAR α [51]. FXR has an additional role in regulating carbohydrate metabolism although some of the published data have been conflicting; FXR agonists can suppress gluconeogenesis and increase glycogen synthesis [52,53], whilst FXR null mice have fasting hypoglycaemia with decreased hepatic expression of gluconeogenic enzymes as well as decreased hepatic glycogen content [54,55].

If limiting FXR activation by *AKR1D1* knockdown was the only mechanism responsible for our observations, some of our data would conflict with the published literature. Obeticholic acid (semi-synthetic bile acid analogue) treatment of human liver slices increased the expression of both SLC51A and B [56], and this mirrors the observations we made in our *AKR1D1* knockdown experiments. An explanation for these findings may lie in analysis of the composition of the bile acid pool following *AKR1D1* knockdown. The differing affinities of both primary and secondary bile acids to activate (or antagonize) bile acid receptors are well described [57] and, therefore, this may also offer an explanation as to why our observations are not rescued by simple FXR receptor agonism. Importantly, in patients with NAFLD, whilst total faecal primary bile acid levels are increased in comparison with healthy controls, there is a disproportionate increase in CDCA compared to CA [18] although in this study, circulating bile acid levels were not measured.

The role of LXR receptor activation to regulate lipogenic gene expression, including *SREBF1*, *FASN*, *ACC1* and *SCD1*, has been well described [58–60]. In our study, treatment with the LXR α antagonist 22-S hydroxycholesterol reduced the effect of *AKR1D1* knockdown on lipogenic gene expression, although to a lesser extent when compared to FXR agonism. The role of LXR β in hepatic lipogenesis has been conflicting. A study from Repa et al. [61] revealed reduced lipogenic gene expression in LXR α , but not LXR β , deficient mice; in contrast, in a

more recent study, LX β deficiency reduced the effects of the synthetic LXR ligand T0901317 on lipogenic gene expression in mice [62]. In our work, LXR β antagonism partially restored the effects of *AKR1D1* knockdown on lipogenic gene expression, highlighting, in total, the additive role of LXRs in the metabolic phenotype observed following *AKR1D1* knockdown.

Inflammation and liver injury are hallmarks in NAFLD/NASH; lipid accumulation within hepatocytes has also been proposed to trigger the activation of inflammatory pathways [63]. Further insight in NAFLD pathophysiology has implicated bile acids in the prevalence of inflammation with increased generation of toxic hydrophobic bile acids that result in cholestatic, inflamed livers. In this work, genetic manipulation of *AKR1D1* expression and activity regulated the inflammatory response in human hepatoma cells by enhancing the expression and secretion of pro-inflammatory cytokines alongside activation of the NF- κ B pathway. In line with this, a significant number of studies have linked cholestasis and consequent liver inflammation and dysfunction with mutations in *AKR1D1* [64–66]. It is thought that these mutations lead to increased levels of bile acid precursors, allo-bile acids (bile acids produced via 5 α R activity) and low levels of CDCA (due to 27-hydroxylase activity and induction of the alternative pathway), which can then drive liver injury.

There is increasing evidence on the role of FXR as a regulator of cellular inflammation and immune response; activation of the receptor induces the expression of anti-inflammatory genes [67] as well as suppressing NF- κ B activation by negative regulation of inflammatory gene expression in the liver [68]. GW4064 has been reported to decrease hepatic inflammation, both *in vitro* and *in vivo*, by reducing the expression of pro-inflammatory cytokines [69,70]. In our study, GW4064 restored IL-1 β mRNA expression in Huh7 cells, only. This finding, in combination with the observed I κ B α degradation caused by *AKR1D1* knockdown, suggests that *AKR1D1* regulates inflammatory response in a both NF- κ B-dependent and NF- κ B-independent way of action. (Supplementary Fig. 9).

5. Conclusions

In conclusion, we have shown that *AKR1D1* is down-regulated across the spectrum of NAFLD, and that this drives a detrimental impact on hepatocyte lipid accumulation and inflammation. Further studies are clearly warranted to explore both the mechanisms by which this occurs as well as the potential to manipulate activity to alter NAFLD progression.

Author contributions

Study development, N.N., L.L.G. and J.W.T.; Methodology, N.N., C.G., N.J.D., L.H.; Investigation, N.N., L.M., S.A., C.G., M.v.d.B., C.M., B.S., R.S.G., A.A., B.A.H.; Writing - Original draft, N.N., S.A., J.W.T.; Writing - Review & Editing, N.N., W.A., H.U.M., T.P., J.R., L.H., J.W.T.; Supervision, W.A., L.H., J.W.T.; Funding Acquisition, J.W.T.

Funding and acknowledgements

This work was supported by the Medical Research Council (programme grant to JWT ref. MR/P011462/1, unit support to RDC MC_U142661184); NIHR Oxford Biomedical Research Centre (principal investigator award to JWT); British Heart Foundation (senior fellowship to LH ref. FS/15/56/31645); National Institute of Environmental Health Sciences (P30-ES013508 awarded to TMP); NIHR Birmingham Biomedical Research Centre (Principal investigator award to W.A.). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health or the National Institute of Environmental Health.

Declaration of Competing Interest

Nothing to declare. TMP is a consultant for Research Institute for Fragrance Materials, is a recipient of a sponsored research agreement from Forendo, and is founding director of Penzymes, LLC.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.metabol.2019.153947>.

References

- [1] Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015;61(5):1547–54. <https://doi.org/10.1002/hep.27368>.
- [2] Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Non-alcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015;148(3):547–55. <https://doi.org/10.1053/j.gastro.2014.11.039>.
- [3] Mody A, White D, Kanwal F, Garcia JM. Relevance of low testosterone to non-alcoholic fatty liver disease. *Cardiovasc Endocrinol* 2015;4(3):83.
- [4] Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. *World J Gastroenterol* 2013. <https://doi.org/10.3748/wjg.v19.i40.6735>.
- [5] Kumarendran B, O'Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. *PLoS Med* 2018;15(3):e1002542.
- [6] Thieringer R, Balkovec J, Chen H, Frazier E, Le Grand C, Metzger J, et al. A novel non-steroidal inhibitor of 11 β -hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models. *Endocr Abstr* 2004;7:P47.
- [7] Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, et al. Loss of 5 α -reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. *Endocrinology* 2013;154(12). <https://doi.org/10.1210/en.2013-1592>.
- [8] Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R, Grinbergs AEK, Davies NP, et al. Dual-5 α -reductase inhibition promotes hepatic lipid accumulation in man. *J Clin Endocrinol Metab* 2016;101(1):103–13. <https://doi.org/10.1210/jc.2015-2928>.
- [9] Nikolaou N, Gathercole, L.L., Kirkwood, L., Dunford, J.E., Hughes, B.A., Gilligan, L.C., et al., 2019. *AKR1D1* regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. *J Steroid Biochem Mol Biol* 189: 218–27. <https://doi.org/10.1016/j.jsmb.2019.02.002>.
- [10] Chen M, Penning TM. 5 β -Reduced steroids and human Δ 4-3-ketosteroid 5 β -reductase (*AKR1D1*). *Steroids* 2014;83:17–26. <https://doi.org/10.1016/j.steroids.2014.01.013>.
- [11] Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR α . *Nature* 1996;383(6602):728–31. <https://doi.org/10.1038/383728a0>.
- [12] Yang Z-X, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. *Hepatol Int* 2010;4(4):741–8. <https://doi.org/10.1007/s12072-010-9202-6>.
- [13] Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *J Lipid Res* 2010;51(4):771–84. <https://doi.org/10.1194/jlr.M001602>.
- [14] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015;385(9972):956–65. [https://doi.org/10.1016/S0140-6736\(14\)61933-4](https://doi.org/10.1016/S0140-6736(14)61933-4).
- [15] Ahn, S.B., Jang, K., Jun, D.W., Lee, B.H., Shin, K.J., 2014. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. *Dig. Dis. Sci* 59(1573-2568 (Electronic)): 2975–82.
- [16] Westerbacka J, Yki-Järvinen H, Vehkavaara S, Häkkinen AM, Andersson R, Wake DJ, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5 β -reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. *J Clin Endocrinol Metab* 2003;88(10):4924–31. <https://doi.org/10.1210/jc.2003-030596>.
- [17] Valanejad, L., Ghareeb, M., Shiffka, S., Nadolny, C., Chen, Y., Guo, L., et al., 2018. Dysregulation of Δ 4-3-oxosteroid 5 β -reductase in diabetic patients: implications and mechanisms. *Mol Cell Endocrinol* 470: 127–41. <https://doi.org/10.1016/j.mce.2017.10.005>.
- [18] Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. *PLoS ONE* 2016;11(5). <https://doi.org/10.1371/journal.pone.0151829>.
- [19] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005. <https://doi.org/10.1002/hep.20701>.
- [20] Green CJ, Charlton CA, Wang L-MM, Silva M, Morten KJ, Hodson L. The isolation of primary hepatocytes from human tissue: optimising the use of small non-encapsulated liver resection surplus. *Cell Tissue Bank* 2017. <https://doi.org/10.1007/s10561-017-9641-6>.

- [21] Semple RK, Sleight A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. *J Clin Invest* 2009;119(2):315–22. <https://doi.org/10.1172/JCI37432>.
- [22] Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 2001;29(9):e45. <https://doi.org/10.1093/nar/29.9.e45>.
- [23] Lample S, Batty E, Attar M, Buck D, Bowden R, Lunter G, et al. Improved workflows for high throughput library preparation using the transposome-based nextera system. *BMC Biotechnol* 2013;13(1):104. <https://doi.org/10.1186/1472-6750-13-104>.
- [24] Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29(1):15–21. <https://doi.org/10.1093/bioinformatics/bts635>.
- [25] Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the reference human genome annotation for the ENCODE project. *Genome Res* 2012;22(9):1760–74. <https://doi.org/10.1101/gr.135350.111>.
- [26] Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014;30(7):923–30. <https://doi.org/10.1093/bioinformatics/btt656>.
- [27] Law CW, Chen Y, Shi W, Smyth GK. 2014. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 15(2):R29. <https://doi.org/10.1186/gb-2014-15-2-r29>.
- [28] Green CJ, Pramfalk C, Morten KJ, Hodson L. From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. *Am J Physiol Endocrinol Metab* 2014;308(1):E1–20. <https://doi.org/10.1152/ajpendo.00192.2014>.
- [29] Donthoffer H. Quantitative estimation of lipids in needle biopsy sized specimens of cadaver liver; 1974 [Acta Medica Academiae Scientiarum Hungaricae].
- [30] Hoyumpa AM, Greene HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. *Am J Dig Dis* 1975. <https://doi.org/10.1007/BF01070758>.
- [31] Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, Abdelmalek MF, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2013. <https://doi.org/10.1053/j.gastro.2013.07.047>.
- [32] Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. *Hepatology* 2014. <https://doi.org/10.1002/hep.26661>.
- [33] Fujita K, Nozaki Y, Yoneda M, Wada K, Takahashi H, Kirikoshi H, et al. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. *Alcohol Clin Exp Res* 2008;34(s1):S18–24. <https://doi.org/10.1111/j.1530-0277.2008.00756.x>.
- [34] Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology* 2014;146(3):726–35. <https://doi.org/10.1053/j.gastro.2013.11.049>.
- [35] Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. *Diabetes Metab* 2003;29(5):478–85. [https://doi.org/10.1016/S1262-3636\(07\)70061-7](https://doi.org/10.1016/S1262-3636(07)70061-7).
- [36] Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. *Cell Metab* 2015;21(5):739–46. <https://doi.org/10.1016/j.cmet.2015.04.004>.
- [37] Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. *Science* 2001;291(5513).
- [38] Keembiyehetty C, Augustin R, Carayannopoulos M.O., Steer S., Manolescu A., Cheeseman, C.I., et al., 2006. Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. *Mol Endocrinol* (Baltimore, Md.) 20(3): 686–97. <https://doi.org/10.1210/me.2005-0010>.
- [39] Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. *Am J Pathol* 2009;174(4):1544–52. <https://doi.org/10.2353/ajpath.2009.080596>.
- [40] Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression. [Review]. *Biochem J* 1993;295:329–41.
- [41] Takanaga H, Chaudhuri B, Frommer WB. GLUT1 and GLUT9 as major contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor. *Biochim Biophys Acta Biomembr* 2008;1778(4):1091–9. <https://doi.org/10.1016/j.bbmem.2007.11.015>.
- [42] Müller C, Assimacopoulos-Jeanet F, Mosimann F, Schneiter P, Riou JP, Pachioudi C, et al. Endogenous glucose production, gluconeogenesis and liver glycogen concentration in obese non-diabetic patients. *Diabetologia* 1997;40(4):463–8. <https://doi.org/10.1007/s001250050701>.
- [43] Clore JN, Post EP, Bailey DJ, Nestler JE, Blackard WG. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast. *J Clin Endocrinol Metab* 1992;74(3):660–6.
- [44] Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 1999. [https://doi.org/10.1016/S1097-2765\(00\)80348-2](https://doi.org/10.1016/S1097-2765(00)80348-2).
- [45] Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Peláez F, et al. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. *J Biol Chem* 2004. <https://doi.org/10.1074/jbc.M306422200>.
- [46] Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. *Trends Pharmacol Sci* 2009;30(11):570–80. <https://doi.org/10.1016/j.tips.2009.08.001>.
- [47] Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. *Diabetes Metab* 2008;34(6 Pt 2):685–91. [https://doi.org/10.1016/S1262-3636\(08\)74605-6](https://doi.org/10.1016/S1262-3636(08)74605-6).
- [48] Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. *J Biol Chem* 2006. <https://doi.org/10.1074/jbc.M510258200>.
- [49] Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces non-alcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. *J Pharmacol Exp Ther* 2009;328(1):116–22. <https://doi.org/10.1124/jpet.108.144600>.
- [50] Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 2004;113(10):1408–18. <https://doi.org/10.1172/JCI200421025>.
- [51] Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J.-C., Staels B., 2003. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. *Mol Endocrinol* (Baltimore, Md.) 17(2): 259–72. <https://doi.org/10.1210/me.2002-0120>.
- [52] De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. *J Biol Chem* 2003. <https://doi.org/10.1074/jbc.M305079200>.
- [53] Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc Natl Acad Sci* 2006;103(4):1006–11. <https://doi.org/10.1073/pnas.0506982103>.
- [54] Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, et al. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. *FASEB J* 2012;26(7):3021–31. <https://doi.org/10.1096/fj.11-195701>.
- [55] Cariou B, Van Harmelen K, Duran-Sandoval D, Van Dijk T, Grefhorst A, Bouchaert E, et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. *FEBS Lett* 2005. <https://doi.org/10.1016/j.febslet.2005.06.033>.
- [56] Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. *J Hepatol* 2016;64(5):1158–66. <https://doi.org/10.1016/j.jhep.2016.01.016>.
- [57] Fiorucci S, Distrutti E., 2015. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. *Trends in Molecular Medicine*: 702–14. <https://doi.org/10.1016/j.molmed.2015.09.001>.
- [58] Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. *Genes Dev* 2000;14(22):2831–8. <https://doi.org/10.1101/gad.850400>.
- [59] Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. *J Biol Chem* 2002;277(13):11019–25. <https://doi.org/10.1074/jbc.M111041200>.
- [60] Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. *Mol Cell Biol* 2001;21(9): 2991–3000. <https://doi.org/10.1128/MCB.21.9.2991-3000.2001>.
- [61] Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JMA, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. *Genes Dev* 2000;14(22):2819–30. <https://doi.org/10.1101/gad.844900>.
- [62] Ducheix S, Montagner A, Polizzi A, Lasserre F, Marmugi A, Bertrand-Michel J, et al. Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. *J Hepatol* 2013;58(5):984–92. <https://doi.org/10.1016/j.jhep.2013.01.006>.
- [63] Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. *Dig Dis Sci* 2016;1294–303. <https://doi.org/10.1007/s10620-016-4049-x>.
- [64] Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ, et al. Mutations in SRD5B1 (AKR1D1), the gene encoding δ 4-3-oxosteroid 5β-reductase, in hepatitis and liver failure in infancy. *Gut* 2003;52(10):1494–9. <https://doi.org/10.1136/gut.52.10.1494>.
- [65] Palermo M, Marazzi MG, Hughes Ba, Stewart PM, Clayton PT, Shackleton CHL. Human Δ4-3-oxosteroid 5β-reductase (AKR1D1) deficiency and steroid metabolism. *Steroids* 2008;73(4):417–23. <https://doi.org/10.1016/j.steroids.2007.12.001>.
- [66] Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5β-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. *J Biol Chem* 2010;285(32):24529–37. <https://doi.org/10.1074/jbc.M110.127779>.
- [67] Zhao A, Lew JL, Huang L, Yu J, Zhang T, Hrywna Y, et al. Human kininogen gene is transactivated by the farnesoid X receptor. *J Biol Chem* 2003;278(31):28765–70. <https://doi.org/10.1074/jbc.M304568200>.
- [68] Wang Y.-D., Chen W.-D., Wang M., Yu D., Forman B.M., Huang W., 2008. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. *Hepatology* (Baltimore, Md.) 48(5): 1632–43. <https://doi.org/10.1002/hep.22519>.
- [69] Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. *Pharm Res* 2013;30(5):1447–57. <https://doi.org/10.1007/s11095-013-0986-7>.
- [70] Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. *World J Gastroenterol* 2014;20(39):14430–41. <https://doi.org/10.3748/wjg.v20.i39.14430>.